September 18, 2018 – MONTREAL, QUEBEC – Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it will be launching its first organic whole hemp extract product line under the LeefyLyfe® brand in Europe and the United Kingdom (“U.K.”).
The Company has completed all of the LeefyLyfe® digital assets ahead of the New Farm Bill in the US, which is expected to pass in the coming weeks. The Company has targeted Europe for its initial launch of the company’s organically sourced CBD brand. The European Leefylyfe® products will be sourced from locally grown organically Hemp Cannabis Sativa and manufactured in EU-GMP and organic certified suppliers.
LeefyLyfe® products will be made strictly from whole plant, full spectrum organic hemp oil containing CBD, CBN, CBV, CBG, minerals, vitamins, flavonoids, terpenes and phenols. The initial product line will include three (3) SKUs including a 5% (500mg) and a 10% (1000mg) oil drops and a 25mg oil in softgels capsules.
Following a positive launch in the European markets, the LeefyLyfe® brand will be rolled out in Europe as early as this fall, and in the United States as legal context allows. Further launches are also envisioned in other jurisdictions around the world.
Aurelio Useche, CEO of Relevium stated: “ With major changes currently underway in the United States to change the legal status of Hemp and CBD, we believe this to be a significant growth driver for the nutraceutical industry. Mr. Useche continued “We are eager to grow our LeefyLyfe® CBD brand in Europe this Fall and following the successful launch, we will aim to expand our product offerings in the United States and abroad”
About Relevium Technologies
Relevium is a publicly-traded company that operates in the $3.7 trillion-dollar worldwide wellness industry. Relevium is focused on the development, acquisition, marketing and sale of consumer products that are derived from cannabis and industrial hemp and other ingredients that are generally accepted as safe. The Company uses cannabinoids and ingredients that have achieved GRAS status (generally accepted as safe) to create brands that are sold via wholesale channels, retail channels and online distribution.
Relevium markets its products as dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals. The Company plans on unveiling a complete line of dietary supplements for consumers derived from Cannabis Sativa and Cannabis Indica. The Company’s initial focus will be on creating a full spectrum extract rich in CBD (cannabidiol) which will be marketed and sold throughout Europe and North America. Relevium is also focused on developing a complete line of supplements, nutraceuticals, sports nutrition and cosmeceuticals. Relevium’s products and brands such as Bioganix® have achieved market penetration and now sold at some of the world’s largest retailers such as Walmart.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
President and CEO
For more information about this press release: